NorthRock Partners’s West Pharmaceutical WST Stock Holding History

NorthRock Partners’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-524	Closed	-$207K	–	867
2024 Q1	$207K	Buy	+524	New	+$194K	0.01%	575

Other funds holding WST

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

NorthRock Partners's WST Position: Q2 2024 in Review

NorthRock Partners sold out of West Pharmaceutical (WST) in Q2 2024, closing a stake of 524 shares — an estimated $207K sold.

NorthRock Partners first reported a position in WST in Q1 2024 and held it in 1 quarter. The position peaked at $207K in Q1 2024. 776 funds tracked by Wall St. Rank hold WST as of Q2 2024.

NorthRock Partners reported no remaining West Pharmaceutical position as of Q2 2024 after selling out during the quarter.
NorthRock Partners sold 524 West Pharmaceutical shares in Q2 2024, an estimated $207K.
NorthRock Partners first reported a position in West Pharmaceutical in Q1 2024 and held it in 1 quarter.
NorthRock Partners's West Pharmaceutical position peaked at $207K in Q1 2024.
776 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2024.

Based on NorthRock Partners's 13F filing for Q2 2024, filed 6 Aug 2024.